Baseline characteristics by race and ethnicity in the real world
| Key variable of interest, n (%) unless specified . | Hispanic (n = 152) . | Non-Hispanic Asian (n = 78) . | Non-Hispanic Black (n = 68) . | Non-Hispanic White (n = 992) . |
|---|---|---|---|---|
| Age, median (range), y | 58.3 (23.9-80.6) | 61.8 (21.5-82.1) | 55.5 (21.5-84.4) | 63.0 (19.6-90.8) |
| Age ≥65 | 37 (24) | 27 (35) | 16 (24) | 411 (41) |
| Male sex | 98 (64) | 41 (53) | 42 (62) | 663 (67) |
| ECOG PS ≥2 before infusion | 4 (3) | 9 (12) | 1 (1) | 44 (4) |
| Elevated LDH at initial diagnosis | 38 (25) | 22 (28) | 17 (25) | 303 (31) |
| HCT-CI score before infusion | ||||
| 0 | 67 (44) | 29 (37) | 16 (24) | 300 (30) |
| 1 | 24 (16) | 17 (22) | 11 (16) | 178 (18) |
| 2 | 32 (21) | 9 (12) | 10 (15) | 115 (12) |
| ≥3 | 29 (19) | 23 (29) | 31 (46) | 399 (40) |
| Disease histology at diagnosis | ||||
| DLBCL | 119 (78) | 61 (78) | 61 (90) | 803 (81) |
| PMBCL | 4 (3) | 2 (3) | 2 (3) | 30 (3) |
| HGBL | 29 (19) | 15 (19) | 5 (7) | 159 (16) |
| With MYC and BCL2 and/or BCL6 rearrangements | 26 (17) | 13 (17) | 4 (6) | 147 (15) |
| NOS | 3 (2) | 2 (3) | 1 (1) | 12 (1) |
| Key comorbidities∗ | ||||
| Pulmonary, moderate to severe | 30 (20) | 14 (18) | 28 (41) | 289 (29) |
| Prior cancer | 10 (7) | 8 (10) | 4 (6) | 166 (17) |
| Obesity (BMI >35 kg/m2) | 15 (10) | 1 (1) | 9 (13) | 90 (9) |
| Renal, moderate to severe, or prior renal implant | 2 (1) | 1 (1) | 1 (1) | 28 (3) |
| Histologic transformation | 37 (24) | 18 (23) | 17 (25) | 300 (30) |
| Disease sensitivity before infusion | ||||
| Sensitive | 44 (29) | 19 (24) | 16 (24) | 213 (21) |
| Resistant | 93 (61) | 53 (68) | 46 (68) | 662 (67) |
| Unknown | 15 (10) | 6 (8) | 6 (9) | 117 (12) |
| No. of lines of prior therapies, median (range) | 3 (2-8) | 3 (1-12) | 3 (1-8) | 3 (1-18) |
| 1-2 | 40 (26) | 19 (24) | 17 (25) | 275 (28) |
| ≥3 | 102 (67) | 54 (69) | 49 (72) | 691 (70) |
| Unknown | 10 (7) | 5 (6) | 2 (3) | 26 (3) |
| Prior HCT (any type) | 32 (21) | 22 (28) | 17 (25) | 305 (31) |
| Prior ASCT | 31 (20) | 21 (27) | 17 (25) | 290 (29) |
| Bridging therapy (any type)† | 31 (20) | 12 (15) | 11 (16) | 224 (23) |
| Year of axi-cel infusion | ||||
| 2018 or before | 46 (30) | 20 (26) | 21 (31) | 284 (29) |
| 2019 | 66 (43) | 36 (46) | 29 (43) | 466 (47) |
| 2020 | 40 (26) | 22 (28) | 18 (26) | 242 (24) |
| ≥12 mo from diagnosis to infusion | 88 (58) | 47 (60) | 51 (75) | 572 (58) |
| ≥28 d from leukapheresis to lymphodepleting chemotherapy | 75 (49) | 37 (47) | 42 (62) | 488 (49) |
| Estimated trial eligibility for ZUMA-1‡ | ||||
| Eligible | 80 (53) | 39 (50) | 23 (34) | 426 (43) |
| Ineligible | 72 (47) | 39 (50) | 45 (66) | 566 (57) |
| Key variable of interest, n (%) unless specified . | Hispanic (n = 152) . | Non-Hispanic Asian (n = 78) . | Non-Hispanic Black (n = 68) . | Non-Hispanic White (n = 992) . |
|---|---|---|---|---|
| Age, median (range), y | 58.3 (23.9-80.6) | 61.8 (21.5-82.1) | 55.5 (21.5-84.4) | 63.0 (19.6-90.8) |
| Age ≥65 | 37 (24) | 27 (35) | 16 (24) | 411 (41) |
| Male sex | 98 (64) | 41 (53) | 42 (62) | 663 (67) |
| ECOG PS ≥2 before infusion | 4 (3) | 9 (12) | 1 (1) | 44 (4) |
| Elevated LDH at initial diagnosis | 38 (25) | 22 (28) | 17 (25) | 303 (31) |
| HCT-CI score before infusion | ||||
| 0 | 67 (44) | 29 (37) | 16 (24) | 300 (30) |
| 1 | 24 (16) | 17 (22) | 11 (16) | 178 (18) |
| 2 | 32 (21) | 9 (12) | 10 (15) | 115 (12) |
| ≥3 | 29 (19) | 23 (29) | 31 (46) | 399 (40) |
| Disease histology at diagnosis | ||||
| DLBCL | 119 (78) | 61 (78) | 61 (90) | 803 (81) |
| PMBCL | 4 (3) | 2 (3) | 2 (3) | 30 (3) |
| HGBL | 29 (19) | 15 (19) | 5 (7) | 159 (16) |
| With MYC and BCL2 and/or BCL6 rearrangements | 26 (17) | 13 (17) | 4 (6) | 147 (15) |
| NOS | 3 (2) | 2 (3) | 1 (1) | 12 (1) |
| Key comorbidities∗ | ||||
| Pulmonary, moderate to severe | 30 (20) | 14 (18) | 28 (41) | 289 (29) |
| Prior cancer | 10 (7) | 8 (10) | 4 (6) | 166 (17) |
| Obesity (BMI >35 kg/m2) | 15 (10) | 1 (1) | 9 (13) | 90 (9) |
| Renal, moderate to severe, or prior renal implant | 2 (1) | 1 (1) | 1 (1) | 28 (3) |
| Histologic transformation | 37 (24) | 18 (23) | 17 (25) | 300 (30) |
| Disease sensitivity before infusion | ||||
| Sensitive | 44 (29) | 19 (24) | 16 (24) | 213 (21) |
| Resistant | 93 (61) | 53 (68) | 46 (68) | 662 (67) |
| Unknown | 15 (10) | 6 (8) | 6 (9) | 117 (12) |
| No. of lines of prior therapies, median (range) | 3 (2-8) | 3 (1-12) | 3 (1-8) | 3 (1-18) |
| 1-2 | 40 (26) | 19 (24) | 17 (25) | 275 (28) |
| ≥3 | 102 (67) | 54 (69) | 49 (72) | 691 (70) |
| Unknown | 10 (7) | 5 (6) | 2 (3) | 26 (3) |
| Prior HCT (any type) | 32 (21) | 22 (28) | 17 (25) | 305 (31) |
| Prior ASCT | 31 (20) | 21 (27) | 17 (25) | 290 (29) |
| Bridging therapy (any type)† | 31 (20) | 12 (15) | 11 (16) | 224 (23) |
| Year of axi-cel infusion | ||||
| 2018 or before | 46 (30) | 20 (26) | 21 (31) | 284 (29) |
| 2019 | 66 (43) | 36 (46) | 29 (43) | 466 (47) |
| 2020 | 40 (26) | 22 (28) | 18 (26) | 242 (24) |
| ≥12 mo from diagnosis to infusion | 88 (58) | 47 (60) | 51 (75) | 572 (58) |
| ≥28 d from leukapheresis to lymphodepleting chemotherapy | 75 (49) | 37 (47) | 42 (62) | 488 (49) |
| Estimated trial eligibility for ZUMA-1‡ | ||||
| Eligible | 80 (53) | 39 (50) | 23 (34) | 426 (43) |
| Ineligible | 72 (47) | 39 (50) | 45 (66) | 566 (57) |
ASCT, autologous stem cell transplantation; BMI, body mass index; DLBCL, diffuse LBCL; ECOG PS, Eastern Cooperative Oncology Group performance status; HCT-CI, HCT-specific comorbidity index; HGBL, high-grade B-cell lymphoma; LDH, lactate dehydrogenase; no., number; NOS, not otherwise specified; PMBCL, primary mediastinal LBCL.
Comorbidities were assessed per Sorror et al.18
The incidence of bridging therapy was derived from the number of patients who initiated a prior therapy after leukapheresis and before conditioning chemotherapy.
The rates of ZUMA-1 trial eligibility used adapted eligibility criteria and were estimated based on available registry data.